You are currently viewing a new version of our website. To view the old version click .

648 Results Found

  • Review
  • Open Access
30 Citations
11,538 Views
16 Pages

BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer

  • Sarah Lidagoster,
  • Reuben Ben-David,
  • Benjamin De Leon and
  • John P. Sfakianos

16 February 2024

Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or muscle invasive). Patients with muscle-invasive disease will be offered a radical treatment combined with systemic therap...

  • Review
  • Open Access
7 Citations
3,186 Views
12 Pages

Auxotrophic Mycobacterium bovis BCG: Updates and Perspectives

  • Odir Antônio Dellagostin,
  • Sibele Borsuk,
  • Thaís Larré Oliveira and
  • Fabiana Kömmling Seixas

Mycobacterium bovis BCG has been used for a century as the only licensed vaccine against tuberculosis. Owing to its strong adjuvant properties, BCG has also been employed as an oncological immunotherapeutic as well as a live vaccine vector against ot...

  • Review
  • Open Access
4 Citations
4,040 Views
9 Pages

14 July 2024

Non-muscle-invasive bladder cancer (NMIBC) encompasses approximately three-quarters of all bladder cancer (BC) diagnoses. Intravesical Bacillus Calmette-Guerin (BCG) has been the long-standing gold standard treatment for patients following endoscopic...

  • Review
  • Open Access
5 Citations
3,795 Views
11 Pages

BCG Vaccine—The Road Not Taken

  • Coad Thomas Dow and
  • Laith Kidess

The Bacillus Calmette-Guérin (BCG) vaccine has been used for over one hundred years to protect against the most lethal infectious agent in human history, tuberculosis. Over four billion BCG doses have been given and, worldwide, most newborns r...

  • Review
  • Open Access
9 Citations
4,761 Views
39 Pages

Recombinant BCG to Enhance Its Immunomodulatory Activities

  • Magdalena Kowalewicz-Kulbat and
  • Camille Locht

The bacillus Calmette–Guérin (BCG) is an attenuated Mycobacterium bovis derivative that has been widely used as a live vaccine against tuberculosis for a century. In addition to its use as a tuberculosis vaccine, BCG has also been found...

  • Article
  • Open Access
3 Citations
3,418 Views
15 Pages

Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN α Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model

  • Sin Mun Tham,
  • Juwita N. Rahmat,
  • Edmund Chiong,
  • Qinghui Wu,
  • Kesavan Esuvaranathan and
  • Ratha Mahendran

25 November 2021

This study evaluates a short therapy schedule for bladder cancer using BCG Tokyo. BCG Tokyo was evaluated in vitro using bone marrow derived dendritic cells, neutrophils, RAW macrophages and the murine bladder cancer cell line, MB49PSA, and compared...

  • Review
  • Open Access
8 Citations
4,265 Views
18 Pages

BCG and SARS-CoV-2—What Have We Learned?

  • Jakub Kulesza,
  • Ewelina Kulesza,
  • Piotr Koziński,
  • Wojciech Karpik,
  • Marlena Broncel and
  • Marek Fol

30 September 2022

Despite controversy over the protective effect of the BCG (Bacille Calmette-Guérin) vaccine in preventing pulmonary tuberculosis (TB) in adults, it has been used worldwide since 1921. Although the first reports in the 1930s had noted a remarka...

  • Article
  • Open Access
12 Citations
1,128 Views
5 Pages

BCG-SSI® vaccine-associated lymphadenitis: Incidence and management

  • Arnis Engelis,
  • Mohit Kakar,
  • Roberts Meikšāns and
  • Aigars Petersons

30 May 2016

Background and objective: There is a high incidence of childhood tuberculosis in Latvia, including children aged less than 1 year, while BCG-associated lymphadenitis is one of the most frequent adverse events requiring surgical treatment. The aim of...

  • Article
  • Open Access
1,579 Views
15 Pages

Immunity Against Mycobacterium avium Induced by DAR-901 and BCG

  • Getahun Abate,
  • Krystal A. Meza,
  • Chase G. Colbert,
  • Octavio Ramos-Espinosa,
  • Nancy J. Phillips and
  • Christopher S. Eickhoff

Background: The prevalence of pulmonary nontuberculous mycobacteria (NTM) is increasing in Europe and North America. Most pulmonary NTM cases are caused by Mycobacterium avium complex (MAC). The treatment of pulmonary MAC is suboptimal with failure r...

  • Article
  • Open Access
3,549 Views
21 Pages

Mycobacterium bovis Wild-Type BCG or Recombinant BCG Secreting Murine IL-18 (rBCG/IL-18) Strains in Driving Immune Responses in Immunocompetent or Immunosuppressed Mice

  • Marek Fol,
  • Marcin Włodarczyk,
  • Magdalena Kowalewicz-Kulbat,
  • Magdalena Druszczyńska,
  • Krzysztof T. Krawczyk,
  • Sebastian Wawrocki,
  • Wiesława Rudnicka and
  • Magdalena Chmiela

14 April 2022

Mycobacterium tuberculosis infections remain a global health problem in immunosuppressed patients. The effectiveness of BCG (Bacillus Calmette–Guérin), an anti-tuberculosis vaccine, is unsatisfactory. Finding a new vaccine candidate is a...

  • Article
  • Open Access
1 Citations
2,009 Views
14 Pages

Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain

  • Hideyuki Isobe,
  • Fumitaka Shimizu,
  • Takeshi Ieda,
  • So Nakamura,
  • Naoko Takazawa,
  • Hanna Suetsugu,
  • Kazunori Kajino,
  • Shu Hirai,
  • Hisashi Hirano and
  • Katsuhito Yuzawa
  • + 1 author

Objectives: The aim of this study was to identify factors that predict recurrence by comparing low-dose and standard-dose Bacillus Calmette-Guérin (BCG) induction therapy in patients with non-muscle invasive bladder cancer (NMIBC). Methods: A...

  • Article
  • Open Access
31 Citations
11,733 Views
19 Pages

Nonclinical Development of BCG Replacement Vaccine Candidates

  • Kamalakannan Velmurugan,
  • Leander Grode,
  • Rosemary Chang,
  • Megan Fitzpatrick,
  • Dominick Laddy,
  • David Hokey,
  • Steven Derrick,
  • Sheldon Morris,
  • David McCown and
  • Reginald Kidd
  • + 5 authors

16 April 2013

The failure of current Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccines, given to neonates to protect against adult tuberculosis and the risk of using these live vaccines in HIV-infected infants, has emphasized the need for generating new,...

  • Article
  • Open Access
16 Citations
4,557 Views
11 Pages

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis

  • Francesco Del Giudice,
  • Rocco Simone Flammia,
  • Benjamin I. Chung,
  • Marco Moschini,
  • Benjamin Pradere,
  • Andrea Mari,
  • Francesco Soria,
  • Simone Albisinni,
  • Wojciech Krajewski and
  • Tomasz Szydełko
  • + 26 authors

10 February 2022

Background: Intravesical immunotherapy with bacillus Calmette–Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The superiority of any BCG strain over another could not be demonstrated yet. Methods:...

  • Article
  • Open Access
6 Citations
6,166 Views
11 Pages

COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population

  • Daniel Garzon-Chavez,
  • Jackson Rivas-Condo,
  • Adriana Echeverria,
  • Jhoanna Mozo,
  • Emmanuelle Quentin,
  • Jorge Reyes and
  • Enrique Teran

27 January 2021

The Bacillus Calmette–Guérin (BCG) is a well-known vaccine with almost a century of use, with the apparent capability to improve cytokine production and epigenetics changes that could develop a better response to pathogens. It has been p...

  • Review
  • Open Access
5 Citations
2,908 Views
16 Pages

Fighting Tuberculosis: In Search of a BCG Replacement

  • Nonna I. Nadolinskaia,
  • Maria S. Kotliarova and
  • Anna V. Goncharenko

Tuberculosis is one of the most threatening infectious diseases and represents an important and significant reason for mortality in high-burden regions. The only licensed vaccine, BCG, is hardly capable of establishing long-term tuberculosis protecti...

  • Article
  • Open Access
7 Citations
3,005 Views
25 Pages

IV BCG Vaccination and Aerosol BCG Revaccination Induce Mycobacteria-Responsive γδ T Cells Associated with Protective Efficacy against M. tb Challenge

  • Alexandra L. Morrison,
  • Charlotte Sarfas,
  • Laura Sibley,
  • Jessica Williams,
  • Adam Mabbutt,
  • Mike J. Dennis,
  • Steve Lawrence,
  • Andrew D. White,
  • Mark Bodman-Smith and
  • Sally A. Sharpe

17 October 2023

Intravenously (IV) delivered BCG provides superior tuberculosis (TB) protection compared with the intradermal (ID) route in non-human primates (NHPs). We examined how γδ T cell responses changed in vivo after IV BCG vaccination of NHPs, a...

  • Article
  • Open Access
6 Citations
3,696 Views
25 Pages

Vaccine-Induced Subcutaneous Granulomas in Goats Reflect Differences in Host–Mycobacterium Interactions between BCG- and Recombinant BCG-Derivative Vaccines

  • Elisabeth M. Liebler-Tenorio,
  • Johannes Heyl,
  • Nadine Wedlich,
  • Julia Figl,
  • Heike Köhler,
  • Gopinath Krishnamoorthy,
  • Natalie E. Nieuwenhuizen,
  • Leander Grode,
  • Stefan H. E. Kaufmann and
  • Christian Menge

20 September 2022

Tuberculous granulomas are highly dynamic structures reflecting the complex host–mycobacterium interactions. The objective of this study was to compare granuloma development at the site of vaccination with BCG and its recombinant derivatives in...

  • Case Report
  • Open Access
1 Citations
616 Views
4 Pages

Granuloma of Epididymis in a Patient Treated with Intravesical BCG Therapy—Complication of BCG Therapy or Tuberculosis?

  • Dorota Michałowska-Mitczuk,
  • Sylwia Brzezińska,
  • Ewa Augustynowicz-Kopeć and
  • Renata Langfort

15 June 2011

We present a case of a 72-year-old man treated for superficial bladder carcinoma from the year 2007. The patient underwent a surgical intervention for transitional cell carcinoma of the bladder, followed by intravesical BCG immunotherapy. Two years l...

  • Article
  • Open Access
6 Citations
3,773 Views
10 Pages

Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain Mycobacterium bovis BCG SL222 Sofia

  • Stefan Panaiotov,
  • Yordan Hodzhev,
  • Vladimir Tolchkov,
  • Borislava Tsafarova,
  • Alexander Mihailov and
  • Tzvetelina Stefanova

Mycobacterium bovis bacillus Calmette–Guérin (BCG) is the only live attenuated vaccine available against tuberculosis. The first BCG vaccination was done exactly 100 years ago, in 1921. The BCG vaccine strains used worldwide represent a family of dau...

  • Article
  • Open Access
10 Citations
3,341 Views
14 Pages

Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages

  • Carina C. dos Santos,
  • Kimberley V. Walburg,
  • Suzanne van Veen,
  • Louis G. Wilson,
  • Carlos E. M. Trufen,
  • Ivan P. Nascimento,
  • Tom H. M. Ottenhoff,
  • Luciana C. C. Leite and
  • Mariëlle C. Haks

Tuberculosis (TB) is one of the top 10 leading causes of death worldwide. The recombinant BCG strain expressing the genetically detoxified A subunit of the thermolabile toxin from Escherichia coli (LTAK63) adjuvant (rBCG-LTAK63) has previously been s...

  • Review
  • Open Access
17 Citations
11,961 Views
9 Pages

31 December 2021

In 2021, most of the world was reasonably still concerned about the COVID-19 pandemic, how cases were up and down in different countries, how the vaccination campaigns were ongoing, and most people were familiar with the speed with which vaccines aga...

  • Perspective
  • Open Access
8 Citations
4,496 Views
9 Pages

The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air

  • Radha Gopalaswamy,
  • Natarajan Ganesan,
  • Kalamani Velmurugan,
  • Vivekanandhan Aravindhan and
  • Selvakumar Subbian

16 October 2020

COVID-19, caused by a novel coronavirus, SARS-CoV-2, contributes significantly to the morbidity and mortality in humans worldwide. In the absence of specific vaccines or therapeutics available, COVID-19 cases are managed empirically with the passive...

  • Article
  • Open Access
6 Citations
5,246 Views
14 Pages

Optimisation of Mycobacterium bovis BCG Fermentation and Storage Survival

  • Jordan Pascoe,
  • Charlotte L. Hendon-Dunn,
  • Colin P.D. Birch,
  • Gareth A. Williams,
  • Mark A. Chambers and
  • Joanna Bacon

Mycobacterium bovis Bacillus Calmette–Guérin (M. bovis BCG) was generated over a century ago for protection against Mycobacterium tuberculosis (Mtb) and is one the oldest vaccines still in use. The BCG vaccine is currently produced using...

  • Article
  • Open Access
2,474 Views
12 Pages

Clinical Application of Monitoring Vital Signs in Dogs Through Ballistocardiography (BCG)

  • Bolortuya Chuluunbaatar,
  • YungAn Sun,
  • Kyerim Chang,
  • HoYoung Kwak,
  • Jinwook Chang,
  • WooJin Song and
  • YoungMin Yun

24 March 2025

This study evaluated the application of the BCG Sense1 wearable device for monitoring the heart rate (HR) and the respiratory rate (RR) in dogs, comparing its performance to the gold standard ECG under awake and anesthetized conditions. Data were col...

  • Review
  • Open Access
9 Citations
5,186 Views
18 Pages

Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis

  • Reginaldo G. Bastos,
  • Heba F. Alzan,
  • Vignesh A. Rathinasamy,
  • Brian M. Cooke,
  • Odir A. Dellagostin,
  • Raúl G. Barletta and
  • Carlos E. Suarez

14 January 2022

Babesiosis is a disease caused by tickborne hemoprotozoan apicomplexan parasites of the genus Babesia that negatively impacts public health and food security worldwide. Development of effective and sustainable vaccines against babesiosis is currently...

  • Article
  • Open Access
4 Citations
4,594 Views
9 Pages

Bacillus Calmette–Guérin (BCG) vaccine is the only licensed vaccine against tuberculosis (TB) in humans and animals. It is most commonly administered parenterally, but oral delivery is highly advantageous for the immunisation of cattle a...

  • Article
  • Open Access
12 Citations
4,226 Views
15 Pages

BCG Provides Short-Term Protection from Experimental Cerebral Malaria in Mice

  • Julia Witschkowski,
  • Jochen Behrends,
  • Roland Frank,
  • Lars Eggers,
  • Linda von Borstel,
  • David Hertz,
  • Ann-Kristin Mueller and
  • Bianca E. Schneider

9 December 2020

Clinical and experimental evidence suggests that the tuberculosis vaccine BCG offers protection against unrelated pathogens including the malaria parasite. Cerebral malaria (CM) is the most severe complication associated with Plasmodium falciparum in...

  • Article
  • Open Access
5 Citations
2,692 Views
12 Pages

Protective Efficacy of BCG Vaccination in Calves Vaccinated at Different Ages

  • Jayne C. Hope,
  • Hamza Khalid,
  • Michelle L. Thom,
  • Chris J. Howard and
  • Darren J. Shaw

Mycobacterium bovis, the causative agent of bovine tuberculosis (bTB), is a globally prevalent pathogen with significant animal welfare, economic and public health impacts. In the UK, the control of bTB relies on detection via tuberculin skin tests w...

  • Communication
  • Open Access
6 Citations
2,314 Views
9 Pages

The Induction of Antigen 85B-Specific CD8+ T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice

  • Shihoko Komine-Aizawa,
  • Satoru Mizuno,
  • Akira Kawano,
  • Satoshi Hayakawa,
  • Kazuhiro Matsuo and
  • Mitsuo Honda

Mycobacterium tuberculosis (Mtb) infection remains a major health problem worldwide. Although the Bacillus Calmette-Guérin (BCG) vaccine is the most widely used vaccination for preventing tuberculosis (TB), its efficacy is limited. We previous...

  • Review
  • Open Access
16 Citations
5,499 Views
20 Pages

Fiction and Facts about BCG Imparting Trained Immunity against COVID-19

  • Gurpreet Kaur,
  • Sanpreet Singh,
  • Sidhanta Nanda,
  • Mohammad Adeel Zafar,
  • Jonaid Ahmad Malik,
  • Mohammad Umar Arshi,
  • Taruna Lamba and
  • Javed Naim Agrewala

23 June 2022

The Bacille Calmette-Guérin or BCG vaccine, the only vaccine available against Mycobacterium tuberculosis can induce a marked Th1 polarization of T-cells, characterized by the antigen-specific secretion of IFN-γ and enhanced antiviral re...

  • Review
  • Open Access
12 Citations
6,570 Views
14 Pages

30 March 2024

Bladder cancer is the 10th most popular cancer in the world, and non-muscle-invasive bladder cancer (NMIBC) is diagnosed in ~80% of all cases. Treatments for NMIBC include transurethral resection of the bladder tumor (TURBT) and intravesical instilla...

  • Communication
  • Open Access
8 Citations
4,271 Views
7 Pages

COVID-19 Severity and Neonatal BCG Vaccination among Young Population in Taiwan

  • Wei-Ju Su,
  • Chia-Hsuin Chang,
  • Jiun-Ling Wang,
  • Shu-Fong Chen and
  • Chin-Hui Yang

Background: Data have not been reported to explore the relation between COVID-19 severity and BCG vaccination status at the individual patient level. Methods: Taiwan has a nationwide neonatal BCG vaccination program that was launched in 1965. The Tai...

  • Article
  • Open Access
2 Citations
2,587 Views
18 Pages

Comparison of the Immunogenicity and Efficacy of rBCG-EPCP009, BCG Prime-EPCP009 Booster, and EPCP009 Protein Regimens as Tuberculosis Vaccine Candidates

  • Ruihuan Wang,
  • Xueting Fan,
  • Da Xu,
  • Machao Li,
  • Xiuqin Zhao,
  • Bin Cao,
  • Chengyu Qian,
  • Jinjie Yu,
  • Dan’ang Fang and
  • Yujie Gu
  • + 2 authors

22 November 2023

Bacillus Calmette–Guérin (BCG) is the only widely used prophylactic tuberculosis (TB) vaccine that can prevent severe TB in infants. However, it provides poor protection in adults, and therefore, there is ongoing research into new TB vac...

  • Article
  • Open Access
94 Citations
11,969 Views
30 Pages

Effect of Experimental Parameters on Alginate/Chitosan Microparticles for BCG Encapsulation

  • Liliana A. Caetano,
  • António J. Almeida and
  • Lídia M.D. Gonçalves

11 May 2016

The aim of the present study was to develop novel Mycobacterium bovis bacille Calmette-Guérin (BCG)-loaded polymeric microparticles with optimized particle surface characteristics and biocompatibility, so that whole live attenuated bacteria could be...

  • Communication
  • Open Access
3 Citations
2,966 Views
12 Pages

Intratumoral PD1+CD38+Tim3+ CD8+ T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer

  • Debashree Basak,
  • Soumya Mondal,
  • Swadeep Kumar Srivastava,
  • Deborpita Sarkar,
  • Ishita Sarkar,
  • Sukanya Basu,
  • Arpita Bhoumik,
  • Snehanshu Chowdhury,
  • Dilip Kumar Pal and
  • Shilpak Chatterjee

26 July 2023

Intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) is a standard of care therapy for non-muscle invasive bladder cancer (NMIBC), which accounts for about 75% of newly diagnosed urothelial cancer. However, given the frequent recurren...

  • Article
  • Open Access
1 Citations
2,330 Views
12 Pages

Comparison Between Simple Batch and Fed-Batch Bioreactor Cultivation of Recombinant BCG

  • Sarah Mendes,
  • Maria C. P. Gonçalves,
  • Vitoria A. P. Aiex,
  • Ryhára D. Batista,
  • Patrícia Zorzete,
  • Luciana C. C. Leite and
  • Viviane M. Gonçalves

Background/Objectives: Tuberculosis continues to be a significant global health concern, causing 1.3 million deaths in 2022, particularly affecting children under 5 years old. The Bacillus Calmette-Guérin (BCG) vaccine, developed in 1921, rema...

  • Article
  • Open Access
9 Citations
3,092 Views
14 Pages

3 February 2022

BCG has shown the ability to induce protection against unrelated pathogens, which likely depends on an immune mechanism known as innate immune memory or trained immunity. In this study, we evaluated the induction of innate memory by a recombinant BCG...

  • Article
  • Open Access
13 Citations
6,568 Views
12 Pages

To assess the Bacille Calmette-Guérin (BCG) vaccination coverage in Zhejiang province and to investigate predictors of the BCG vaccination, we used data from the 2017 Zhejiang provincial coverage survey. Demographic and immunization data on th...

  • Article
  • Open Access
43 Citations
15,492 Views
20 Pages

BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study

  • Mitsuyoshi Urashima,
  • Katharina Otani,
  • Yasutaka Hasegawa and
  • Taisuke Akutsu

Ecological studies have suggested fewer COVID-19 morbidities and mortalities in Bacillus Calmette–Guérin (BCG)-vaccinated countries than BCG-non-vaccinated countries. However, these studies obtained data during the early phase of the pandemic and did...

  • Article
  • Open Access
1 Citations
2,513 Views
23 Pages

The Cellular and Transcriptomic Early Innate Immune Response to BCG Vaccination in Mice

  • Liya G. Kondratyeva,
  • Olga A. Rakitina,
  • Victor V. Pleshkan,
  • Alexey I. Kuzmich,
  • Irina A. Linge,
  • Sofia A. Kondratieva,
  • Eugene V. Snezhkov,
  • Irina V. Alekseenko and
  • Eugene D. Sverdlov

11 December 2024

It is established that BCG vaccination results in the development of both a specific immune response to mycobacterial infections and a nonspecific (heterologous) immune response, designated as trained immunity (TRIM), to other pathogens. We hypothesi...

  • Article
  • Open Access
3 Citations
3,283 Views
16 Pages

Immunogenicity and Protection against Mycobacterium caprae Challenge in Goats Vaccinated with BCG and Revaccinated after One Year

  • Claudia Arrieta-Villegas,
  • Enric Vidal,
  • Maite Martín,
  • Judit Verdés,
  • Xavier Moll,
  • Yvonne Espada,
  • Mahavir Singh,
  • Bernardo Villarreal-Ramos,
  • Mariano Domingo and
  • Bernat Pérez de Val

10 December 2020

Vaccination has been proposed as a supplementary tool for the control of tuberculosis in livestock. The long-term immunogenicity elicited by bacillus Calmette–Guerin (BCG) and the efficacy of revaccination were investigated in thirty goat kids...

  • Feature Paper
  • Article
  • Open Access
463 Views
11 Pages

Non-Specific Cross Protection of BCG Vaccination in Dairy Calves

  • Renata López,
  • Valentina Villarroel,
  • Víctor Neira,
  • Carolina Aguayo,
  • Karina Saadi,
  • Katherinne Orozco,
  • Pedro Abalos and
  • Patricio Retamal

16 October 2025

Bovine tuberculosis (bTB) is mainly caused by Mycobacterium bovis, which affects cattle, leading to significant economic losses. In Chile, the vaccination with the M. bovis Bacillus Calmette-Guérin (BCG) strain has been implemented in dairy he...

  • Article
  • Open Access
1,583 Views
12 Pages

Transcriptional Profiling of Homologous Recombination Pathway Genes in Mycobacterium bovis BCG Moreau

  • Marcos Gustavo Araujo Schwarz,
  • Paloma Rezende Corrêa and
  • Leila Mendonça-Lima

Mycobacterium bovis BCG Moreau is the main Brazilian strain for vaccination against tuberculosis. It is considered an early strain, more like the original BCG, whereas BCG Pasteur, largely used as a reference, belongs to the late strain clade. BCG Mo...

  • Case Report
  • Open Access
8 Citations
3,331 Views
4 Pages

NOD2 Mutation-Associated Case with Blau Syndrome Triggered by BCG Vaccination

  • Akiko Arakawa,
  • Naotomo Kambe,
  • Ryuta Nishikomori,
  • Akiyo Tanabe,
  • Masamichi Ueda,
  • Chikako Nishigori,
  • Yoshiki Miyachi and
  • Nobuo Kanazawa

6 February 2021

We describe a patient who developed multiple granulomatous skin lesions after Bacille de Calmette et Guérin (BCG) vaccination without significant effect by topical corticosteroid, followed by painless cystic tumors on the bilateral knees and hands an...

  • Case Report
  • Open Access
1 Citations
1,782 Views
9 Pages

Molecular Identification of Extrapulmonary Vaccine Adverse Events after BCG in Paraffin-Embedded Specimens

  • Sylwia Brzezińska,
  • Anna Zabost,
  • Dagmara Borkowska-Tatar,
  • Magdalena Klatt,
  • Jolanta Goździk,
  • Agnieszka Dłużniewska,
  • Katarzyna Błasińska and
  • Ewa Augustynowicz-Kopeć

21 November 2023

According to the World Health Organization (WHO), around 1 million children worldwide are diagnosed with tuberculosis each year. The Bacillus Calmette–Guérin (BCG) vaccine has been used around the world for over 100 years. The complicati...

  • Article
  • Open Access
1 Citations
1,851 Views
15 Pages

22 February 2025

Background and Objectives: Intravesical Bacillus Calmette-Guérin (BCG) therapy remains a cornerstone in the treatment of non-muscle-invasive bladder carcinoma due to its efficacy in reducing recurrence and progression rates. However, its use i...

  • Review
  • Open Access
19 Citations
7,350 Views
15 Pages

Bacille Calmette–Guerin (BCG) vaccination is widely practiced around the world to protect against the mycobacterial infection tuberculosis. BCG is also effective against the pathogenic mycobacteria that cause leprosy and Buruli’s ulcer. B...

  • Article
  • Open Access
3 Citations
3,964 Views
15 Pages

Protease-Based Subunit Vaccine in Mice Boosts BCG Protection against Mycobacterium tuberculosis

  • Ana Paula Junqueira-Kipnis,
  • Carine de Castro Souza,
  • Ana Carolina de Oliveira Carvalho,
  • Fabio Muniz de Oliveira,
  • Vinnycius Pereira Almeida,
  • Alisson Rodrigues de Paula,
  • Mara Rubia Celes and
  • André Kipnis

16 February 2022

The significant number of people with latent and active tuberculosis infection requires further efforts to develop new vaccines or improve the Bacillus Calmette-Guérin (BCG), which is the only approved vaccine against this disease. In this stu...

  • Article
  • Open Access
1 Citations
2,019 Views
12 Pages

Impact of Genomic Deletion RD16 on the Expression of the Mycobacterium bovis BCG Moreau VapBC47 Toxin-Antitoxin System

  • Talita Duarte Pagani,
  • Paloma Rezende Corrêa,
  • Cristiane Lima,
  • Leonardo Henrique Ferreira Gomes,
  • Marcos Gustavo Araujo Schwarz,
  • Teca Calcagno Galvão,
  • Wim Maurits Degrave,
  • Napoleão Fonseca Valadares and
  • Leila Mendonça-Lima

Mycobacterium bovis BCG is the only vaccine against tuberculosis. The variable forms of cultivation throughout the years, before seed-lots were developed, allowed in vitro evolution of the original strain, generating a family of vaccines with differe...

of 13